Holen Sie sich die Stockscreener-App
2.62
6.09%
-0.17
Handel nachbörslich:
2.63
0.010
+0.38%
Schlusskurs vom Vortag:
$2.79
Offen:
$2.72
24-Stunden-Volumen:
58,067
Relative Volume:
0.06
Marktkapitalisierung:
$124.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-17.87%
1M Leistung:
-83.62%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.62
$2.8047
1-Wochen-Bereich:
$2.62
$3.41
52-Wochen-Spanne:
$2.201
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Firmenname
Polaryx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.62 | 132.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polaryx Therapeutics Inc Aktie (PLYX) Neueste Nachrichten
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
PLYX | Polaryx Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ - EIN News
Polaryx Therapeutics (PLYX) 10K Form and SEC Filings 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Price, News & Analysis - MarketBeat
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
Insider Buying: G. Landis Acquires Shares of Polaryx Therapeutics Inc (PLYX) - GuruFocus
PLYX Stock Price, News & Analysis - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
What's Going On With Polaryx Therapeutics Stock Wednesday? - Benzinga
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Polaryx selects CRO for phase 2 trial of rare disease treatment - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans - Bitget
SMJ INTERNATIONAL HOLDINGS INC. (SMJF) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics Surges Amid Strategic Market Moves - StocksToTrade
Polaryx Therapeutics Sees Strategic Moves Amid Market Volatility - timothysykes.com
Polaryx selects CRO for Soteria Phase 2 trial - TipRanks
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx Therapeutics selects contract research organization for Soteria phase 2 basket trial - marketscreener.com
Rare-disease biotech readies Phase 2 trial across four childhood disorders - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FORTUNE BRANDS INNOVATIONS, INC. (FBIN) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Polaryx Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
NUSCALE POWER CORPORATION (SMR) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx to evaluate PLX-200 for Krabbe disease in Phase 2 trial - Investing.com South Africa
Polaryx announces pre-clinical data related to Soteria - TipRanks
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ - The Manila Times
In mice with Krabbe disease, Polaryx drug restored movement, extended life - Stock Titan
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings - Benzinga
Morning Market Movers: UOKA, KD, HIMS, PGY See Big Swings - RTTNews
Strategy, Bitmine Immersion Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Polaryx appoints Mitchel Berger, Francis Braun, Charles Ryan to board - TipRanks
Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline - simplywall.st
Cerence Inc. (CRNC) - MSN
Eli Lilly and Oracle among market cap stock movers on Thursday - Investing.com
Polaryx Therapeutics, Inc. Announces Board Changes, Effective January 29, 2026 - marketscreener.com
Finanzdaten der Polaryx Therapeutics Inc-Aktie (PLYX)
Es liegen keine Finanzdaten für Polaryx Therapeutics Inc (PLYX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):